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Detection of human microdeletion and microduplication syndromes poses significant burden on public healthcare systems in
developing countries. With genome-wide diagnostic assays frequently inaccessible, targeted low-cost PCR-based approaches are
preferred.However, their reproducibility depends on equally efficient amplification using a number of target and control primers. To
address this, the recently described technique called Microdeletion/Microduplication Quantitative Fluorescent PCR (MQF-PCR)
was shown to reliably detect four human syndromes by quantifying DNA amplification in an internally controlled PCR reaction.
Here, we confirm its utility in the detection of eight humanmicrodeletion syndromes, including the more commonWAGR, Smith-
Magenis, and Potocki-Lupski syndromes with 100% sensitivity and 100% specificity. We present selection, design, and performance
evaluation of detection primers using variety of approaches.We conclude thatMQF-PCR is an easily adaptablemethod for detection
of human pathological chromosomal aberrations.
1. Introduction
Repetitive DNA accounts for more than 50% of human
genome [1] and is one of the primary driving forces of
evolution of all eukaryotes. While mostly harmless, stretches
of highly similar sequences flanking genes with essential
functions create hotspots prone to undergo unequal recom-
bination during meiosis. The resulting pathological copy
number variations (CNVs) [2] include microscopic and
submicroscopic deletions and duplications (microdeletions
and microduplications) that have been implicated as etio-
logic factors in many human clinical syndromes. Molecular
diagnosis of these aberrations has significantly evolved in
resolution from simple metaphase karyotyping to genome-
wide molecular screens [3, 4]. However, there are serious
limitations to the widespread use of complex diagnostic
assays, especially the high cost and rapid obsolescence of the
necessary equipment, expensive supplies, and the need for
high technical expertise. As a result, pangenomic diagnostic
approaches remain scarce in developing countries, where
oftenmicrodeletion andmicroduplication syndromes remain
undiagnosed.We have described recently the development of
a simple, rapid, and inexpensive targeted PCR-based CNV
detection method called Microdeletion/Microduplication
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Figure 1: Experimental design and visualization of microdeletion detection using MQF-PCR. (a) Schematic representation of MQF-PCR
primer design. Control region with high sequence similarity to the microdeletion critical region and containing 1–10 bp insertion/deletion
(empty box) is used to design MQF-PCR primer pair (arrows) that amplifies two fragments of distinct size. The forward primer is extended
at 5󸀠 end using M13-40 universal sequence (black box) to allow cost-efficient M13-40-NED fluorescent labeling and reliable quantification of
fluorescent signal intensity, while the reverse primer is extended at 5󸀠 end using the PIG-tail (grey box) to improve adenylation of the 3󸀠 end
of the forward strand. (b)–(i) Representative electropherograms showing the change in peak areas corresponding to the syndrome-related
chromosomes (black) and the peaks representing the control chromosomes (white) between controls and affected individuals. In all panels,
approximately 50% reduction in the peak areas in the affected individuals is observed. Approximate chromosomal locations of theMQF-PCR
amplicons are shown.
Quantitative Fluorescent PCR (MQF-PCR) [5]. In our origi-
nal report, we developed assays for two common microdele-
tion syndromes, the Williams-Beuren syndrome (7q11.23
microdeletion) and the 22q11.2microdeletion syndromes and
discovered that MQF-PCR could detect both with 100% sen-
sitivity and 100% specificity. Additionally, we demonstrated
that the same principle could be reliably used for detection of
microduplication syndromes, by using samples from patients
with the Lubs (MECP2 duplication) syndrome and the 17q11.2
microduplication involving the NF1 gene [5].
Now, we present the development of MQF-PCR primer
pairs to detect several othermicrodeletion syndromes:Wilms
tumour, aniridia, genitourinary anomalies, and mental retar-
dation syndrome (WAGR; OMIM: 194072), Smith-Magenis
(OMIM: 182290), Potocki-Lupski (OMIM: 610883), microd-
eletions at Xp22.3 (OMIM: 308100, 308700), Langer-Giedion
(OMIM: 150230), Greig cephalopolysyndactyly (OMIM:
175700), Miller-Dieker lissencephaly (OMIM: 247200), and
Saethre-Chotzen (OMIM: 101400) syndromes.
2. Materials and Methods
2.1. Ethics Statement. DNA samples previously diagnosed
with known microdeletion syndromes at GENE-Nu´cleo de
Gene´ticaMe´dica, BeloHorizonte,MG,were anonymized and
used in testing the diagnostic procedure. The participants
did not provide written or verbal consent and no other
formal documented measures were taken. This procedure
was approved by the Ethics Committee of Santa Casa de
Miserico´rdia in Belo Horizonte with the registration number
CEP 009/2008. WAGR patients were recruited through the
International WAGR Syndrome Association. The study was
approved by the institutional review board of the National
Institute of Child Health and Human Development. Writ-
ten informed consent was obtained from adults who were
competent to provide consent and from the parents or legal
guardians of children and adults with cognitive impairment.
Assent was obtained from patients who were unable to give
consent. Patient samples with Smith-Magenis and Potocki-
Lupski syndromes were collected after informed consent was
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Table 1: List of MQF-PCR primers.
Syndrome/region Primer name Genomic locations (GRCh37); fragmentsize Sequence (5
󸀠
→ 3
󸀠)
WAGR [6]
∼244 kb downstream fromWT1
WAGR-MQF-F chr11:32166342-32166440; 118 bp AGAATGCAGTGAYACAAAGGa
WAGR-MQF-R chr17:53032677-53032764; 107 bp GGAGGTAGGTAAATCAATCAb
Smith-Magenis/Potocki-Lupski [7]
∼9 kb upstream from TOM1L2
SMS-MQF-F chr17:17884450-17884584; 155 bp TACATTAGAAAAAGAGAGCTGGa
SMS-MQF-R chr1:100679142-100679278; 157 bp CATCATCCTGTTCCCCTTTGb
Xp22.3 [8]
KAL1
Xp22-MQF-F chrX:8572701-8572822; 136 bp GAGACCACTGAGGGTAACTa
Xp22-MQF-R chr11:114279747-114279863; 142 bp AATTTTGAGCATCCTGAAAb
Langer-Giedion [9]
∼63 kb downstream from UTP23
LGS-MQF-F chr8:117842056-117842177; 142 bp AGCAATGGCCATTCCTTAGAa
LGS-MQF-R chr4:174188668-174188791; 144 bp CCATGCAGCACCCYTCATb
Greig cephalopolysyndactyly [10]
GLI3
GCS-MQF-F chr7:42088115-42088183; 93 bp TGCWGAGATCATGGAGAGCa
GCS-MQF-R chr2:121708925-121708996; 89 bp TACRTKAAYCCCYACATGGAb
Miller-Dieker [11]
CRK
MDS-MQF-F chr17:1340129-1340311; 208 bp TGATTCTCAGGCAGGAGGAa
MDS-MQF-R chr17:6962293-6962479; 211 bp CGACGTAAGGRACTGGAATCb
Saethre-Chotzen [12]
∼46 kb downstream from TWIST1
SCS-MQF-F chr7:19108525-19108628; 124 bp TGGATATTTGTGYTAYTTCCTTa
SCS-MQF-R chr1:195731420-195731527; 128 bp TGCATACTMCACAATTAATTRTGTGb
aUniversal M13-40 extension (5󸀠-GTTTTCCCAGTCACGAC-3󸀠) was added to the 5󸀠 end of the primer for cost-efficient fluorescent labeling of amplicons [13].
bA PIG-tail extension (5󸀠-GTTTCTT-3󸀠) was added to the 5󸀠 end of the primer to promote complete adenylation of the 3󸀠 end of the forward strand [13].
Table 2: MQF-PCR detection of eight human microdeletion syndromes.
Syndrome Patient Z-statistics score
WAGR
3.3 −5.14
6.3A −5.23
8.3 −5.72
17.3A −5.47
18.3A −5.41
21.3 −5.55
24.3A −5.55
29.3C −5.44
GM06803 −6.97
Smith-Magenis
SMS105 −4.42
SMS123 −5.19
SMS135 −4.18
SMS162 −4.27
SMS167 −3.69
SMS170 −4.38
SMS179 −2.93
SMS182 −4.87
SMS217 −4.26
SMS293 −4.18
SMS336 −5.48
Potocki-Lupski
SMS224 2.81
SMS338 5.64
11166 8.72
Xp22.3 Simulated patient 0.01 ± 0.14a
Langer-Giedion GM09888 −7.40
12550 −7.12
Greig cephalopolysyndactyly GM10925 −3.12
Miller-Dieker lissencephaly GM09208 −6.36
Saethre-Chotzen 10051 −6.43
aArithmetic mean of Z-scores, standard deviation of mean.
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Figure 2: Performance of MQF-PCR in detection of various CNVs. Interactive dot diagrams of ROC curve analysis of Z-score
statistics in WAGR (a), Smith-Magenis (b), Potocki-Lupski (c), and Xp22.3 deletion detection (d). The MQF-PCR primers achieved 100%
detection sensitivity and 100% detection specificity. Box-and-Whisker plot of Z-score statistics obtained for Langer-Giedion (e), Greig
cephalolysyndactyly (f), Miller-Dieker lissencephaly (g), and Saethre-Chotzen (h) microdeletion syndromes. Positive samples (full circle)
are shown as outliers. In all panels, the number of controls and patients analyzed is given.
obtained and in accordance with local institutional review
board approved protocols from Virginia Commonwealth
University and/or Michigan State University.
2.2. Patients. Genomic DNA from normal male and female
individuals and from individuals previously diagnosed with
microdeletion syndromes diagnosed at GENE Nu´cleo de
Gene´tica Me´dica, Belo Horizonte, MG, Brazil, was isolated
as described [5]. WAGR sample GM06803 was obtained
from Coriell Cell Repositories (Camden, New Jersey, USA).
The remaining WAGR samples diagnosed by genome-wide
aCGHwere described previously [6]. DNA samples of Smith-
Magenis and Potocki-Lupski patients diagnosed by FISH or
metaphase karyotyping were published previously [7]. In
order to simulate Xp22.3 microdeletions, we used normal
female and male samples as control individuals and affected
samples, respectively.The Saethre-Chotzen syndrome patient
10051 had microdeletion at 7p21.1 diagnosed by aCGH. The
Langer-Giedion syndrome patient 12550 showed cytogeneti-
cally visible partial deletion of the long arm of chromosome
8 and was diagnosed at our clinic. The remaining samples
were obtained from Coriell Cell Repositories: GM09888
(Langer-Giedion), GM10925 (Greig cephalopolysyndactyly),
and GM09208 (Miller-Dieker lissencephaly).
2.3. MQF-PCR Primer Selection, Assay Design, and Analysis.
MQF-PCR takes advantage of the presence of highly similar
sequences in distinct parts of human genome, which differ in
length by a few base pairs (Figure 1(a)). A detailed literature
search of previously publishedmolecular genetic analyseswas
performed for each of the syndromes in order to determine
minimal critical regions suitable forMQF-PCRprimer design
(Table 1, GRCh37 human genome assembly) [6–12, 14].These
regions were used as queries in Basic Local Alignment Search
Tool (http://blast.ncbi.nlm.nih.gov/). A single PCR primer
pair (arrows in Figure 1(a)) was then designed, capable of
amplification of two fragments, one that locates to the critical
genomic region of disease and another, shorter or longer, that
serves as CNV-free control fragment (Figure 1(a); Table 1).
In order to reliably quantify the differently sized amplicons,
we employed a cost-efficient method of fluorescent labeling
of PCR products with the common M13-40-NED primer
(Figure 1(a)) [13]. PCR amplification, amplicon separation,
and data collection and analysis were performed as described
in Stofanko et al. [5]. We used Receiver Operating Charac-
teristic (ROC) analysis of the Z or UPZ score statistics [15,
16] using MedCalc v12 (MedCalc Software, Mariakerke, Bel-
gium). Box-and-Whisker plots were also constructed using
MedCalc [17]. 95% confidence intervals of true positives, false
positives, true negatives and false negatives were calculated
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Table 3: Sensitivity and specificity of MQF-PCR tests in detection of WAGR, Smith-Magenis, Potocki-Lupski and simulated Xp22.3
microdeletion syndromes.
Syndrome Probability estimate (95% confidence interval)
True positive False positive True negative False negative
WAGR 100% (66–100%) 0% (0–7%) 100% (93–100%) 0% (0–34%)
Smith-Magenis 100% (72–100%) 0% (0–7%) 100% (93–100%) 0% (0–28%)
Potocki-Lupski 100% (29–100%) 0% (0–7%) 100% (93–100%) 0% (0–71%)
Xp22.3 100% (93–100%) 0% (0–7%) 100% (93–100%) 0% (0–7%)
using the Fisher’s exact test [18] in GraphPad Prism 6
(GraphPad software, CA, USA).
3. Results and Discussion
In affected individuals, because of the deletions or dupli-
cations, the amount of template DNA corresponding to
the syndrome’s critical region is inherently halved or dou-
bled, respectively, in comparison with the control region
when equal amounts of DNA from the affected and control
individuals are dispensed in the assay system. Following
PCR, this translates into an approximately 50% reduction
or increase in the area under the electrophoretic peak of
the amplicon from the critical microdeletion region (Figures
1(b)–1(i)). For example, in the detection of the WAGR
syndrome (Figure 1(b)), we observed in normal controls
a ratio close to 1 : 1 of the peak that corresponds to the
WAGR critical region at 11p13 (black) and the control peak
at 17q22 (white). In a hemizygous patient, the peak area ratio
changed to approximately 1 : 2 (black/white), which reflects
the template DNA dosage change. Similar reduction in peak
area ratios was noted for Smith-Magenis, Langer-Giedion,
Greig cephalopolysyndactyly, Miller-Dieker lissencephaly,
and Saethre-Chotzen syndromes even if the peak area ratio
in controls was not exactly the expected 1 : 1 ratio, presumably
because amplicon-specific factors influence the efficiency of
PCR (Figures 1(c) and 1(e)–1(i)). Figure 1(d) shows detection
of autosomal duplication of 17p11.2 that causes Potocki-
Lupski syndrome. In this patient, the peak area ratio changed
from about 1 : 1 to about 3 : 2 (black/white), which reflects the
template DNA dosage change. Since the number of patients
available for testing is limited in rare syndromes, in the case
of the Xp22.3 deletions (Figure 1(e)) we used female samples
(XX) as controls and male DNA (XY) as a simulated model
for affected patients.This waywe could obtain a better picture
of the performance of ourmethodon a larger scale and extend
its use to include diagnosis of deletions in the Xp22.3 region
in male patients for whom only the control fragment would
be detected. Finally, in order to correct for the observed
uneven amplification efficiency, we normalized our data to
a reference sample of mixed DNA from 100 individuals
that was processed at the same time [5]. Standard deviation
Z-scores or pseudo-Z scores [15] were then calculated for
each sample (Table 2), and the performance of each assay
was evaluated by ROC analysis [16] (Figures 2(a)–2(d)).
Instances with fewer than five positive patients were assessed
using Box-and-Whisker plot [17] (Figures 2(e)–2(h)). We
achieved unbiased and reproducible PCR amplification in
WAGR and Smith-Magenis syndromes and the simulated
Xp22.3 deletions with 100% detection sensitivity and 100%
exclusion specificity. Similarly, the results for patients with
rarer syndromes appeared as outliers in corresponding Box-
and-Whisker plots. The 95% confidence intervals for the
sensitivity and specificity of MQF-PCR tests for WAGR,
Smith-Magenis, Potocki-Lupski, and the simulated Xp22.3
syndromes are shown in Table 3.
It should be noted that a limitation of this protocol
for diagnosing patients with 11p13 region deletions is that
it is 100% sensitive only in patients with aniridia because
the targeted critical region lies between PAX6 (the gene
responsible for aniridia) and WT1 (the gene responsible for
Wilms tumor and genitourinary anomalies); this protocol
would fail to detect 11p13 deletions that involve WT1, but
spare PAX6. Such patients would not be considered to have
classic WAGR syndrome however, and this MQF-PCR could
be easily modified to target other critical regions to diagnose
proximal 11p deletion and/or Potocki-Shaffer syndromes.
4. Conclusion
Here we report development of detection primers for
8 human microdeletion syndromes using the recently
described MQF-PCR. We showed that the method is easily
adaptable to detect any pathological CNVwith high accuracy.
With the expansion of the capability to diagnose even more
disease-related CNVs, MQF-PCR appears to be a reliable,
low cost, and rapid detection method, especially for use in
developing countries.
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